These were the oxazolidinones and a group of quinolone derivatives. The oxazolidinones, bacteriostatic rather than bactericidal, were expensive: it had cost Rhone-Poulenc Rorer $0.5 billion to bring Synercid to the market, and this outlay was reflected in the cost of treatment -up to $250 a day. It was agreed that neither the oxazolidinones nor the quinolones, licensed for human use, would be given to animals, but before long the agricultural industry had got its hands on analogues of both, either for growth-enhancement or for therapy.
There are only four things certain since Social Progress beganThat the Dog returns to his vomit and the Sow returns to her Mire, And the burnt Fool's bandaged finger goes wabbling back to the Fire … Attempts to find new antibiotic substances are not now, it seems, a matter of high priority for Big Pharma. The cost of bringing drugs to market has risen alarmingly, and it is medication for chronic maladies, rather than single-shot cures for infections, that will sustain the profits.
Tuberculosis is still to a large extent a disease of destitute populations, though that is beginning to change. The focus, Shnayerson and Plotkin reveal, has in large measure shifted to vaccines, assisted by genomic strategies and improved procedures for rapid identification of the agents of infection. And perhaps the whole notion of eliminating the wily pathogens once and for all was misconceived: might it not be better to treat infections conservatively, for then the evolutionary advantage will rest with more benign strains, which do not kill their hosts?
There is also now much research on peptides to inhibit the binding of the pathogen to its cell receptors. We welcome correspondence on any article in the journal, but reserve the right to reduce the length of any letter to be published. All Correspondence containing data or scientific argument will be refereed. Items for publication should either be submitted to Current Biology, Elsevier Science London, 84 Theobald's Road, London, WC1X 8RR, UK, or e-mailed to cbiol@current-biology.com
